Get the Stockscreener App
1.89
5.00%
0.09
After Hours:
1.87
-0.02
-1.06%
Genprex Inc stock is traded at $1.89, with a volume of 1.84M.
It is up +5.00% in the last 24 hours and down -43.75% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$1.80
Open:
$1.88
24h Volume:
1.84M
Relative Volume:
2.53
Market Cap:
$4.29M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.1614
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
+7.39%
1M Performance:
-43.75%
6M Performance:
-85.48%
1Y Performance:
-95.68%
1-Day Range:
$1.71
$1.94
1-Week Range:
$1.71
$1.94
52-Week Range:
$1.71
$55.00
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
1.89 | 4.09M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Genprex Reports Positive Preclinical Data for Diabetes Gene Therapy in Animal Studies; Shares Rise - marketscreener.com
Genprex Reports Positive Preclinical Data For Diabetes Gene Therapy Candidate GPX-002 - Nasdaq
Genprex reports positive data for diabetes gene therapy in animal studies By Investing.com - Investing.com South Africa
Genprex Reports Positive Preclinical Results for GPX-002 Diabetes Therapy - TipRanks
Genprex Announces Positive Preclinical Data for GPX-002 in Diabetes - TradingView — Track All Markets
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies - PR Newswire
MSN Money - MSN
Genprex (GNPX) Stock Analysis Report | Financials & Insights - Benzinga Italia
Published on: 2025-12-29 06:37:03 - moha.gov.vn
Genprex reports potential compliance with Nasdaq equity listing rule By Investing.com - Investing.com Canada
Genprex (GNPX) awards 28,500 RSUs to Chief Medical Officer under 2018 plan - Stock Titan
Genprex (GNPX) CEO Ryan Confer reports 45,000 RSUs award - Stock Titan
Genprex (GNPX) grants director 9,000 RSUs after reverse stock split - Stock Titan
Genprex reports potential compliance with Nasdaq equity listing rule - Investing.com
Genprex Updates on Nasdaq Compliance Efforts - TradingView — Track All Markets
Street Watch: Will Genprex Inc stock split attract more investorsMarket Trend Review & Real-Time Stock Movement Alerts - moha.gov.vn
How Genprex Inc. stock reacts to inflationary pressuresWeekly Gains Summary & Safe Entry Momentum Stock Tips - Bölüm Sonu Canavarı
Aug Catalysts: How Genprex Inc. stock reacts to inflationary pressuresQuarterly Profit Review & Verified Chart Pattern Signals - moha.gov.vn
Can Genprex Inc. stock beat market expectations this quarterJuly 2025 Price Swings & Consistent Income Trade Recommendations - Улправда
What catalysts could drive Genprex Inc. stock higherJuly 2025 Setups & Long-Term Capital Growth Strategies - Улправда
How Genprex Inc. stock performs in high volatility marketsInflation Watch & Free Real-Time Market Sentiment Alerts - Улправда
Momentum Shift: Why Genprex Inc stock remains on buy listsEarnings Risk Summary & Fast Moving Stock Watchlists - moha.gov.vn
Will Genprex Inc. (2DE0) stock benefit from mergers2025 Performance Recap & Long-Term Investment Growth Plans - Улправда
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Dividend Watch: Can Genprex Inc. stock beat market expectations this quarterPortfolio Update Report & Technical Confirmation Trade Alerts - Улправда
Why analysts upgrade Genprex Inc. stock2025 Buyback Activity & Fast Moving Stock Watchlists - DonanımHaber
Will Genprex Inc. stock sustain high P E ratios2025 Breakouts & Breakdowns & AI Enhanced Trading Alerts - DonanımHaber
How Genprex Inc. (2DE0) stock reacts to new regulationsQuarterly Portfolio Report & AI Based Trade Execution Alerts - Улправда
Why Genprex Inc. stock is rated strong buyJuly 2025 Final Week & Community Consensus Trade Signals - DonanımHaber
Is Genprex Inc. stock a smart buy before Fed meetingQuarterly Profit Report & Accurate Buy Signal Notifications - DonanımHaber
Genprex Secures U.S. Patent for Reqorsa® Therapy - MSN
Genprex Inc Stock Analysis and ForecastSector-Based Investing & High Yield Market Growth - earlytimes.in
Will Genprex Inc. (2DE0) stock recover faster than industry2025 Analyst Calls & Risk Managed Investment Signals - Newser
Is Genprex Inc. (2DE0) stock undervalued after correctionJuly 2025 PreEarnings & Risk Controlled Daily Trade Plans - Newser
Is Genprex Inc. stock cheap at current valuationWeekly Profit Report & Community Driven Trade Alerts - Newser
Congressman Buys Shares Of Small Cap Lift Truck Company You've Probably Never Heard Of - Benzinga
Can Genprex Inc. (2DE0) stock reach $200 price targetEarnings Growth Summary & Entry and Exit Point Strategies - Newser
Get in on Genprex Inc’s (GNPX) buy-in window today! - setenews.com
Why Genprex Inc. stock remains on buy listsWeekly Profit Summary & Fast Gaining Stock Reports - Newser
Genprex, Inc. Stock (GNPX) Opinions on Recent Preclinical Data Release - Quiver Quantitative
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire) - Aktiellt
Taking the lead: Genprex Inc (GNPX) - Setenews
Genprex regains Nasdaq bid price compliance, receives equity extension By Investing.com - Investing.com Australia
Genprex regains Nasdaq bid price compliance, receives equity extension - Investing.com
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):